Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$68.55 USD

68.55
1,378,444

+1.18 (1.75%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $68.55 0.00 (0.00%) 4:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

National Vision (EYE) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) performance in the fourth quarter of 2021.

Zacks Equity Research

OPKO Health's (OPK) Q4 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

OPKO Health's (OPK) fourth-quarter results benefit from continued strength in its Pharmaceuticals segment.

Zacks Equity Research

Merit Medical's (MMSI) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in both its segments, and from majority of the product categories within its Cardiovascular unit.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) fourth-quarter results benefit from Technologies & Equipment business.

Zacks Equity Research

Inari Medical (NARI) Gains 12.5% Despite In-Line Q4 Earnings

by Zacks Equity Research

Inari Medical's (NARI) fourth-quarter results benefit from significant progress made across all of its growth drivers.

Zacks Equity Research

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein's (HSIC) favorable dental business trends and bullish fourth-quarter 2021 performance.

Zacks Equity Research

Thermo Fisher (TMO) Extends Collaboration With Moderna

by Zacks Equity Research

Thermo Fisher (TMO) continues to be a trusted partner of Moderna, bringing a wide range of products and services enabling Moderna to deliver innovative medicines at an extraordinary speed and scale.

Zacks Equity Research

Here's Why Henry Schein (HSIC) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Henry Schein (HSIC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Thermo Fisher (TMO) COVID Test Sales Grow, FX Woes Persist

by Zacks Equity Research

Thermo Fisher's (TMO) strong pandemic response stance enables it to accelerate its growth strategy, and bump up investments, which encourages it to raise the 2022 core organic growth guidance.

Debanjana Dey headshot

Allscripts' (MDRX) Q4 Earnings Beat Estimates, Margins Up

by Debanjana Dey

Allscripts' (MDRX) robust Q4 results demonstrate strength in both segments.

Zacks Equity Research

Are These Medical Stocks a Great Value Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is Henry Schein (HSIC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Henry Schein (HSIC) and Pharvaris N.V. (PHVS) have performed compared to their sector so far this year.

Zacks Equity Research

Chemed (CHE) Q4 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Chemed (CHE) reports better-than-expected earnings for the fourth quarter, with a robust performance by the Roto-Rooter arm driving the top line.

Zacks Equity Research

Myriad Genetics (MYGN) Reports Loss in Q4, Gross Margin Improves

by Zacks Equity Research

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.

Zacks Equity Research

Teleflex (TFX) Q4 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.

Zacks Equity Research

Nevro's (NVRO) Q4 Earnings in Line, Revenues Beat Estimates

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q4 due to soft geographical performances.

Zacks Equity Research

Avanos Medical (AVNS) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Avanos Medical's (AVNS) fourth-quarter 2021 results gain from strength in the chronic care segment.

Zacks Equity Research

Integra's (IART) Q4 Earnings Top Estimates, Gross Margin Drops

by Zacks Equity Research

Integra (IART) records strong recovery in order demand in Q4 on broad-based strength in Neurosurgery and sales from the company's new CereLink ICP monitoring.

Zacks Equity Research

Insulet (PODD) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Insulet's (PODD) fourth-quarter 2021 revenues improved year over year on a strong performance of Omnipod, both in U.S. and international markets.

Zacks Equity Research

NuVasive (NUVA) Q4 Earnings Miss Estimates, Gross Margin Up

by Zacks Equity Research

Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.

Zacks Equity Research

Amedisys (AMED) Q4 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Robust performances by the Home Health and Hospice segments drove Amedisys' (AMED) fourth-quarter top line.

Zacks Equity Research

Cerner (CERN) Q4 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Cerner's (CERN) fourth-quarter results benefit from gains across four of its business units.

Zacks Equity Research

LHC Group (LHCG) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Despite the weak bottom-line performance, LHC Group's (LHCG) fourth-quarter results benefit from organic growth in home health admissions.

Zacks Equity Research

Abbott (ABT) COVID Testing Sales Surge, FX Headwind Stays

by Zacks Equity Research

Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

Zacks Equity Research

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.